Oxford spinout raises $113M in bid to beat Sarepta's Exondys 51 in DMD. But will we ever know if any of the drugs work?

It’s been five years since the FDA decided to approve Sarepta’s Duchenne muscular dystrophy drug Exondys 51 on a sliver of biological evidence, and …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ox­ford spin­out rais­es $113M in bid to beat Sarep­ta's Ex­ondys 51 in DMD. But will we ever know if any of the drugs work?